Non-alcoholic fatty liver disease epidemiology and demographics

Jump to navigation Jump to search

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease epidemiology and demographics

CDC on Non-alcoholic fatty liver disease epidemiology and demographics

Non-alcoholic fatty liver disease epidemiology and demographics in the news

Blogs on Non-alcoholic fatty liver disease epidemiology and demographics

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

The estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals. The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually. Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years. Hepatic steatosis is more prevalent in the hispanics.

Epidemiology

Incidence

  • The estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals.
  • The estimated annual incidence of non alcoholic liver disease with steatohepatitis in the United States is approximately 265 per 100,000 individuals .
  • About 1/3 of america population is expected to have non alcoholic fatty liver disease.[1][2][3][4][5]

Prevalance

  • The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually.
  • In obese children the prevalence of non-alcoholic liver disease is estimated to be 20,000 to 50,000 cases per 100,000 individuals annually.[6]
  • Prevalence of non-alcoholic fatty liver disease increases nearly five fold in obese individuals.

Demographics

Age

  • Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years.

Gender

  • Men are more commonly affected by non-alcoholic liver disease than women.
  • Among women it is more common in post-menopausal women than pre-menopausal.

Race

  • Hepatic steatosis is more prevalent in the hispanics (45%) race and followed by caucasians (42% of men, 24% of women) and african-american (24%)

References

  1. Bellentani S, Scaglioni F, Marino M, Bedogni G (2010). "Epidemiology of non-alcoholic fatty liver disease". Dig Dis. 28 (1): 155–61. doi:10.1159/000282080. PMID 20460905.
  2. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M (2014). "Non alcoholic fatty liver: epidemiology and natural history". Rev Recent Clin Trials. 9 (3): 126–33. PMID 25514916.
  3. Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC; et al. (2017). "Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States". PLoS One. 12 (3): e0173499. doi:10.1371/journal.pone.0173499. PMC 5367688. PMID 28346543.
  4. Fan JG, Farrell GC (2009). "Epidemiology of non-alcoholic fatty liver disease in China". J Hepatol. 50 (1): 204–10. doi:10.1016/j.jhep.2008.10.010. PMID 19014878.
  5. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  6. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.

Template:WS Template:WH